Akero Therapeutics (AKRO) has been firing on all cylinders with respect to the development of its FGF21 drug efruxifermin which is being developed to treat patients with compensated cirrhosis [F4] due ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results